Diaceutics PLC DXRX Platform Contract Win (4749L)
13 Septiembre 2021 - 01:00AM
UK Regulatory
TIDMDXRX
RNS Number : 4749L
Diaceutics PLC
13 September 2021
13 September 2021
Diaceutics PLC
("Diaceutics" or "the Company")
DXRX platform contract win
Diaceutics PLC (AIM: DXRX), the diagnostic commercialisation
company, is pleased to announce that it has secured a contract with
a global pharmaceutical company for the provision of technology
enabled services, to be delivered via its DXRX platform. The
contract value is in excess of $900,000, with the majority of
revenue to be recognised in the current financial year, supporting
the Company's growth targets and current year forecasts.
Diaceutics will collaborate with the client to support the
launch of a diagnostic test alongside a new oncology drug. Both the
diagnostic test and drug are new to the market and as such the
diagnostic test will require adoption by laboratories globally in
order for the drug to be prescribed by physicians. This initial
contract will involve creating a Quality Assurance standard across
30 laboratories in ten countries to ensure that results and
interpretation are consistent wherever the test is undertaken.
Peter Keeling, CEO and Founder of Diaceutics PLC, commented
:
"We are very pleased to be supporting the commercialisation of
this new oncology drug for our client. This drug has the potential
to help many cancer patients when on the market and the work done
now will mean more patients having access to this drug, earlier.
Through the use of the DXRX platform, we anticipate the study to be
completed swiftly, utilising our growing online lab network ."
Enquiries:
Diaceutics PLC
Philip White, Chief Financial Officer Via Alma PR
Stifel Nicolaus Europe Limited (Nomad & Broker Tel: +44 (0)20 7710
) 7600
Ben Maddison
Stewart Wallace
Nick Adams
Alma PR Tel: +44(0)20 3405
0205
Caroline Forde diaceutics@almapr.co.uk
Robyn Fisher
Kieran Breheny
Matthew Young
About Diaceutics
At Diaceutics we believe that every patient should have access
to the right treatment at the right time. We provide the world's
leading pharmaceutical companies with an end-to-end solution for
the launch of precision medicine diagnostics enabled by DXRX - The
Diagnostic Network(R).
DXRX is the world's first diagnostic commercialisation platform
for precision medicine, integrating multiple pipelines of
real-world diagnostic testing data from a global network of
laboratories.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
CNTLMMFTMTIBBFB
(END) Dow Jones Newswires
September 13, 2021 02:00 ET (06:00 GMT)
Diaceutics (LSE:DXRX)
Gráfica de Acción Histórica
De Feb 2024 a Mar 2024
Diaceutics (LSE:DXRX)
Gráfica de Acción Histórica
De Mar 2023 a Mar 2024